LEAP

Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)

Post Date: 
2019-12-29
Learn more about this effort to foster development of long-lasting therapies for illnesses that require taking medications long-term

Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV

Post Date: 
2019-12-20
Publication: 
Lancet HIV
Lancet HIV: Dr. Bob Bollinger and colleagues discuss the urgent need and opportunity to include activity against Hepatitis B in formulations of long-acting drugs for HIV prevention and treatment

Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities

Post Date: 
2019-07-15
Publication: 
Lancet HIV
Lancet HIV : This paper summarizes findings of the Long acting/Extended Release Antiretroviral Resource Program workshop, and offers recommendations for developing ARV products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women